http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ye Wang,Haojia Su,Zhengchun Cai,Jia Liu,Yien Yuan,Yongxin Ji 한국섬유공학회 2022 Fibers and polymers Vol.23 No.11
Novel cationic macromolecular emulsifier (PD emulsifier) and anionic macromolecular emulsifier (PA emulsifier)were synthesized with acrylate monomer and E-TPA (self-made molecular weight regulator), which were further used toprepare cationic sizing agent (PD-sizing agent) and anionic sizing agent (PA-sizing agent) respectively. On the other hand, ETPAwas synthesized with epoxy resin and S,S'-bis(α,α'-dimethyl-α''-acetic acid)-trithiocarbonate. Because the performanceof sizing agent and macromolecular emulsifier was affected by E-TPA with epoxy resin, the critical micelle concentration,solubilization and molecular weight of the emulsifier with various E-TPA dosages were studied, while the water resistanceand mechanical properties of sizing paper were further researched. The results indicate that the water resistance andmechanical strength can be enhanced with epoxy resin, under the premise that the particle size of the sizing agent is smallenough. The PD-sizing agent with the PD emulsifier of which the amount of E-TPA is 11.63 wt% shows the best sizingproperties with folding endurance of 19, bursting strength of 211 kPa, tensile strength of 72.77 kN/m and the water absorption(cobb) of 54.23 g/m2. The PA-sizing agent with the PA emulsifier containing 11.63 wt% of E-TPA documents the best sizingproperties with tensile strength of 61.49 kN/m, folding endurance of 14, bursting strength of 185.67 kPa and the cobb of47.88 g/m2.
Yun-Qi Wang,Ji-Ye Cai 한국물리학회 2007 Current Applied Physics Vol.7 No.s1
While biodegradable, biocompatible poly(L-lactic acid) (PLLA) is a popular material for the manufacture of tissue engineering scaf-folds, its surface properties are not particularly suitable for cell growth. In the present study, poly(L-lactic acid) (PLLA) lms were fab-ricated by a solution casting method and their surfaces were subsequently modied by NaOH hydrolysis. The changes of surfaceproperties were characterized by contact-angle measurement and atomic force microscopy (AFM). Mouse L929 broblasts were usedas model cells to evaluate the cell anity of PLLA before and after surface modication. The results showed that the hydrophilicity20 nm to between 40 and 200 nm. The adhesion and growth of mouse L929 broblasts on modied lms were signicantly improved.Thus, improved hydrophilicity and increased surface roughness at 40200 nm could signicantly enhance cell adhesion and growth onmodied PLLA that could be useful for applications in tissue engineering.
Zhou, De,Xie, Wan-Zhuo,Hu, Ke-Yue,Huang, Wei-Jia,Wei, Guo-Qing,He, Jing-Song,Shi, Ji-Min,Luo, Yi,Li, Li,Zhu, Jing-Jing,Zhang, Jie,Lin, Mao-Fang,Ye, Xiu-Jin,Cai, Zhen,Huang, He Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.2
Aim: To analyze the significance of different clinical factors for prognostic prediction in diffuse large B-cell lymphoma (DLBCL) patients. Methods: Two hundred and twenty-seven DLBCL patients were retrospectively reviewed. Patients were managed with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen or rituximab plus the CHOP (RCHOP) regimen. Results: Lactate dehydrogenase (LDH), ${\beta}2$-microglobulin (${\beta}2$-M), B symptoms, Ann Arbor stage and genetic subtypes were statistically relevant in predicting the prognosis of the overall survival (OS). In the CHOP group, the OS in patients with germinal center B-cell-like (GCB)(76.2%) was significantly higher than that of the non-GCB group (51.9%, P=0.032). With RCHOP management, there was no statistical difference in OS between the GCB (88.4%) and non-GCB groups (81.9%, P=0.288). Conclusion: Elevated LDH and ${\beta}2$-M levels, positive B symptoms, Ann Arbor stage III/IV, and primary nodal lymphoma indicate an unfavorable prognosis of DLBCL patients. Patients with GCB-like DLBCL have a better prognosis than those with non-GCB when treated with the CHOP regimen. The RCHOP treatment with the addition of rituximab can improve the prognosis of patients with DLBCL.